With antibiotic resistance on the rise at a time when Big Pharma has largely left the risk-heavy field, the President’s Council of Advisors on Science and Technology is proposing a number of recommendations to lure companies back into the arena and help speed up the development of new antibiotics.

…read more

Source: President’s advisory group calls for clinical trial changes, incentives for antibiotics R&D


0 No comments